At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ARWR Arrowhead Pharmaceuticals
Post-Mkt 12-05 19:26:51 EST
61.44
-3.22
-4.98%
盘后61.49
+0.05+0.08%
18:50 EST
High64.28Low60.29Vol3.59M
Open62.95D1 Closing64.66Amplitude6.17%
Mkt Cap8.34BTradable Cap7.31BTotal Shares135.81M
T/O220.86MT/O Rate3.02%Tradable Shares118.91M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Stock Track | Arrowhead Pharmaceuticals Soars 5.01% on FDA Breakthrough Therapy Designation for Plozasiran
Stock Track  ·  12-03
Stock Track | Arrowhead Pharmaceuticals Soars 5.01% on FDA Breakthrough Therapy Designation for Plozasiran
Arrowhead Gets FDA Breakthrough Therapy Designation for Severe Hypertriglyceridemia Drug
Dow Jones  ·  12-02
Arrowhead Gets FDA Breakthrough Therapy Designation for Severe Hypertriglyceridemia Drug
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia
THOMSON REUTERS  ·  12-02
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia
Arrowhead Pharmaceuticals: Intends to Submit a Supplemental New Drug Application (Snda) to FDA by Year-End 2026
THOMSON REUTERS  ·  12-02
Arrowhead Pharmaceuticals: Intends to Submit a Supplemental New Drug Application (Snda) to FDA by Year-End 2026
Arrowhead Pharmaceuticals - to Complete Phase 3 Studies by Mid-2026
THOMSON REUTERS  ·  12-02
Arrowhead Pharmaceuticals - to Complete Phase 3 Studies by Mid-2026
Arrowhead Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $85 From $80
THOMSON REUTERS  ·  12-02
Arrowhead Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $85 From $80
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Catapults 33% Though Its Price And Business Still Lag The Industry
Simply Wall St.  ·  12-02
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Catapults 33% Though Its Price And Business Still Lag The Industry
Arrowhead Pharmaceuticals Director Mauro Ferrari Reports Sale of Common Shares
Reuters  ·  12-02
Arrowhead Pharmaceuticals Director Mauro Ferrari Reports Sale of Common Shares
Stock Track | Arrowhead Pharmaceuticals Soars 8.61% Intraday on FDA Approval of First siRNA Therapy for FCS
Stock Track  ·  12-02
Stock Track | Arrowhead Pharmaceuticals Soars 8.61% Intraday on FDA Approval of First siRNA Therapy for FCS
Stock Track | Arrowhead Pharmaceuticals Soars 8.61% Intraday on FDA Approval of First siRNA Therapy
Stock Track  ·  12-02
Stock Track | Arrowhead Pharmaceuticals Soars 8.61% Intraday on FDA Approval of First siRNA Therapy
Stock Track | Arrowhead Pharmaceuticals Soars 5.08% Intraday on FDA Approval of First siRNA Therapy for FCS
Stock Track  ·  12-01
Stock Track | Arrowhead Pharmaceuticals Soars 5.08% Intraday on FDA Approval of First siRNA Therapy for FCS
Stock Track | Arrowhead Pharmaceuticals Soars 5.08% Intraday After FDA Approval of First siRNA Therapy for FCS
Stock Track  ·  12-01
Stock Track | Arrowhead Pharmaceuticals Soars 5.08% Intraday After FDA Approval of First siRNA Therapy for FCS
Stock Track | Arrowhead Pharmaceuticals Soars 5.08% Intraday After FDA Approval of First siRNA Therapy
Stock Track  ·  12-01
Stock Track | Arrowhead Pharmaceuticals Soars 5.08% Intraday After FDA Approval of First siRNA Therapy
Stock Track | Arrowhead Pharmaceuticals Soars 5.08% Intraday After FDA Approval of First siRNA Therapy
Stock Track  ·  12-01
Stock Track | Arrowhead Pharmaceuticals Soars 5.08% Intraday After FDA Approval of First siRNA Therapy
Arrowhead Pharmaceuticals Is Maintained at Buy by Chardan Capital
Dow Jones  ·  12-01
Arrowhead Pharmaceuticals Is Maintained at Buy by Chardan Capital
Arrowhead Pharmaceuticals (ARWR) Is Up 19.1% After FDA Approval of First siRNA Therapy for FCS
Simply Wall St.  ·  12-01
Arrowhead Pharmaceuticals (ARWR) Is Up 19.1% After FDA Approval of First siRNA Therapy for FCS
Is Arrowhead a Bargain After Clinical Trial Progress Fuels 168% Jump in 2025?
Simply Wall St.  ·  11-30
Is Arrowhead a Bargain After Clinical Trial Progress Fuels 168% Jump in 2025?
Arrowhead falls -8.3%
TIPRANKS  ·  11-29
Arrowhead falls -8.3%
Arrowhead Pharmaceuticals at Risk: Potential Generic Competition Threatens REDEMPLO’s Market Exclusivity
TIPRANKS  ·  11-27
Arrowhead Pharmaceuticals at Risk: Potential Generic Competition Threatens REDEMPLO’s Market Exclusivity
Arrowhead Pharmaceuticals’ Earnings Call Highlights FDA Approval and Strong Financials
TIPRANKS  ·  11-27
Arrowhead Pharmaceuticals’ Earnings Call Highlights FDA Approval and Strong Financials
No data available

Introduction

Company Name.
Arrowhead Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Issue price:
--